A variant t(1;19)(q23;p13.3) translocation creates reciprocal DAZAP1/MEF2D and MEF2D/DAZAP1 fusion genes that are expressed in acute lymphoblastic leukemia. We used retroviral gene transfer to ectopically express wild-type and chimeric DAZAP1 and MEF2D fusion proteins in NIH 3T3 cells. In soft agar assays, each of the fusion proteins transformed 3T3 cells with a 20-fold increase in colony formation as compared to empty vector or native MEF2D or DAZAP1 proteins. Co-expression of both DAZAP1/MEF2D and MEF2D/DAZAP1 led to a threefold increase in colony formation as compared to either fusion protein alone. Expression of wild-type DAZAP1, MEF2D or DAZAP1/MEF2D allowed 3T3 cells to proliferate under low serum (0.5%) conditions and suppressed apoptosis. In contrast, MEF2D/DAZAP1 expression did not facilitate proliferation in low serum and led to a modest increase in apoptosis. Both MEF2D/DAZAP1 and DAZAP1/MEF2D have oncogenic properties, and co-expression of both fusion proteins is synergistic.
Introduction
Chromosome translocations, which are often associated with specific subtypes of leukemias, lymphomas and sarcomas, result in aberrant expression of intact proteins or the generation of chimeric proteins that contribute to malignant transformation. For most reciprocal translocations, only one protein from the two derivative chromosomes is expressed, or, if proteins from both derivatives are expressed, only one contributes significantly to malignant transformation. However, in some hematological malignancies, reciprocal derivative fusion proteins are expressed and both may play a role in transformation and/or the clinical phenotype of disease. 1 One prominent example is provided by PML-RARA and RARA-PML in acute promyelocytic leukemia. 2, 3 Transgenic mouse models of acute promyelocytic leukemia suggest that expression of the reciprocal RARA-PML protein influences disease penetrance, phenotype and treatment response.
Recently, our laboratory and others reported that a variant t(1;19)(q23;p13.3) present in the TS-2 acute lymphoblastic leukemia cell line fuses the 19p13 gene DAZAP1 to the 1q23 gene MEF2D leading to expression of reciprocal in-frame DAZAP1/MEF2D and MEF2D/DAZAP1 fusion transcripts. 4, 5 MEF2D is a member of the MEF2 family of DNA-binding proteins, which activate transcription of genes involved in control of differentiation and survival of lymphoid, neural and muscle cells.
6 DAZAP1 is a novel RNA-binding protein involved in mRNA processing/trafficking that is expressed most abundantly in testis. 7 The reciprocal chimeric proteins created by this t(1;19) include important functional domains of DAZAP1 and MEF2D responsible for protein dimerization, DNA or RNA binding, transcriptional activation and subcellular localization, and might therefore contribute to leukemogenesis by altering signaling pathways normally regulated by wild-type MEF2D and/or DAZAP1. This study was undertaken to evaluate whether one or both of MEF2D and DAZAP1 protein fusions have transforming properties when ectopically expressed in NIH 3T3 cells.
Materials and methods

Cell culture
cDNA fragments encoding human DAZAP1, MEF2D, DAZAP1/ MEF2D and MEF2D/DAZAP1 were FLAG-tagged 5 and cloned into the XhoI site of pMSCVneo or pMSCVhyg vectors (Clontech, Mountain View, CA, USA). A transient-transfection system 8 was used to create retroviruses harboring the DAZAP1 and MEF2D wild-type and fusion cDNAs. Low-passage NIH 3T3 cells (ATCC) were infected with viral supernatant, expanded for 48 h then selected with 0.3-0.6 mg ml À1 G418 sulfate (Invitrogen Life Technologies, Carlsbad, CA, USA) and/or 0.2 mg ml
À1
Hygromycin B (Invitrogen) for 2 to 3 weeks to achieve stable transduction. To co-express both fusion proteins, retroviruses containing different antibiotic resistance markers were employed.
Protein immunoprecipitation and western blot
Immunoprecipitation of FLAG-tagged proteins was performed by consecutive use of the FLAG Tagged Protein IP kit (Sigma, St. Louis, MO, USA) and the One-Step Complete IP-Western kit (GenScript, Piscataway, NJ, USA). Following separation on sodium dodecyl sulfate-polyacrylamide gels, protein expression was determined by immunoblot analysis using the M2 anti-FLAG primary antibody (Sigma) and goat-anti-mouse Ig-HRP secondary antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA). The chemiluminescent signal was detected using the ECL Plus detection kit (Amersham, Arlington Heights, IL, USA).
Soft agar assay
Stably transduced cells were trypsinized, suspended in Dulbecco's modified Eagle's medium (Mediatech, Herndon, VA, USA) containing 0.3% agar and 15% calf serum (CS), plated onto a bottom layer containing 0.6% agar and covered with a top layer containing 0.6% agar. The cells were plated at a density of 3 Â 10 4 per well in a six-well plate, and fed with 1 ml of liquid media weekly. Colonies were stained with crystal violet and counted with ImageQuant TL software (Amersham Biosciences; Piscataway, NJ, USA) 14-17 days following plating, with software parameters adjusted to count colonies consisting of at least 100 cells.
Adherent cell proliferation assay
Cells in Dulbecco's modified Eagle's medium containing 0, 0.5 or 5% CS were dispensed into 24-well plates (5 Â 10 3 cells per well). Cell proliferation was assessed by WST-1-based colorimetric assay at 450 nm (Roche Diagnostics, Roswell, GA, USA).
Apoptosis assay
Cells in Dulbecco's modified Eagle's medium containing 5% CS were seeded at a concentration of 3 Â 10 4 cells per well and cultured overnight. Cells were incubated with 0.5% CS for 5 h, with 5% ethanol (positive control) for 1 h, or left untreated (negative control). Apoptosis was assessed with the APOPercentage assay kit (Accurate Chemical, Westbury, NY, USA). Cells were stained with APOPercentage dye, lysed in 0.1N NaOH, and absorbance values were read at 550 nm.
Results and discussion
We established NIH 3T3 lines stably transduced with expression vectors encoding wild-type MEF2D and DAZAP1 proteins and the chimeric MEF2D/DAZAP1 and DAZAP1/MEF2D fusion proteins ( Figure 1a) . 5 FLAG-tagged recombinant proteins of the predicted size were expressed abundantly immediately following transient transfection of packaging Phoenix cells (Figure 1b) . While all transduced 3T3 cells display neomycin or hygromycin resistance following antibiotic selection, the levels of recombinant proteins expressed following 2 to 3 weeks of selection varied widely, presumably due to differential toxicities of the expressed proteins, with MEF2D/DAZAP1 showing the lowest level of expression (Figure 1c ). We were able to detect all the recombinant proteins in 3T3 cell lysates using anti-FLAG immunoprecipitation (Figure 1d ).
There were striking phenotypic consequences of ectopically expressed fusion proteins, which were most apparent when MEF2D/DAZAP1 and DAZAP1/MEF2D were co-expressed. Morphologically, NIH 3T3 cells expressing both DAZAP1/ MEF2D and MEF2D/DAZAP1 fusion proteins display a dramatic loss of the regular flat, surface-adherent fibroblast phenotype observed in the parental cells (Figure 2a vs. b) . As MEF2D is known to be a direct transcriptional activator of actin, 9 it is possible that MEF2D fusion proteins alter actin microfilament polymerization, with resultant changes in cytoskeleton organization leading to changes in cell shape, motility and adhesion properties. These events are important steps in malignant transformation that may contribute to anchorage-independent growth. 10, 11 To characterize the transforming properties of wild-type and chimeric DAZAP1 and MEF2D proteins, we performed soft agar assays with 3T3 cells stably transduced with empty vector or transgene constructs (Figure 2c ). Only a low background incidence of colonies was observed with empty vector, or either wild-type protein (Figures 2d, e) . In contrast, expression of DAZAP1/MEF2D or MEF2D/DAZAP1 led to approximately 20-fold more colonies than background. The fact that MEF2D/ DAZAP1 transformed 3T3 cells despite very low protein expression as assessed via western blot (Figure 1c) is reminiscent of mixed lineage leukemia fusion proteins that immortalize stably transduced murine cells even though protein levels are undetectable by western blotting. 12 Most notably, approximately 60-fold more colonies than background were observed when DAZAP1/MEF2D and MEF2D/DAZAP1 were coexpressed.
Our data on anchorage-independent growth of transduced 3T3 cells extend prior observations showing increased colony formation in monolayer HeLa cultures overexpressing either DAZAP1/MEF2D or MEF2D/DAZAP1. 4 We observed that DAZAP1 protein, which did not induce anchorage-independent growth, consistently accumulated to very high levels relative to DAZAP1/MEF2D and MEF2D/DAZAP1 fusion proteins Cooperative transformation by MEF2D/DAZAP1 and DAZAP1/MEF2 V Prima and SP Hunger (Figure 1c) . It was unclear whether this was because of more efficient transcription/translation, enhanced stability or reduced toxicity of the protein. Nevertheless, this demonstrated that fusion to MEF2D did not contribute to transformation by simply enhancing stability of wild-type DAZAP1, but rather conferred a gain of function.
To assess serum dependence, we studied growth kinetics of transduced cells in monolayer cultures (Figure 3 ). All cell lines grew well in 5% CS, but not in 0% CS. 3T3 cells expressing DAZAP1, MEF2D, DAZAP1/MEF2D or both DAZAP1/MEF2D and MEF2D/DAZAP1 were still able to proliferate in media containing only 0.5% CS, although cell numbers observed after 10 days in 0.5% CS were 5-to 10-fold lower than numbers present in 5% CS. Interestingly, the cells expressing MEF2D/ DAZAP1 alone, which possess high anchorage-independent growth potential, did not proliferate in 0.5% CS.
To evaluate the extent of apoptosis that occurred in the presence of low serum concentration, we used an apoptosisspecific live dye. This dye is selectively incorporated into apoptotic cells when phosphatidylserine is translocated to the outer leaflet of the plasma membrane, a hallmark of apoptosis. 13 Little apoptosis (3-10% cells; data not shown) was present when cells were grown in 5% CS, while transfer to media with 0% CS-induced apoptosis rapidly in all cell lines (Figure 4a ). Five hours after transfer from 5 to 0.5% CS, 50-60% of cells expressing vector alone, DAZAP1 or MEF2D were undergoing apoptosis. Cells that expressed MEF2D/DAZAP1 displayed a modest increase in apoptosis in 0.5% CS as compared to vector alone. In contrast, cells expressing either DAZAP1/MEF2D or both DAZAP1/MEF2D and MEF2D/DAZAP1 showed a substantial reduction in apoptosis following transfer to 0.5% CS as compared to vector alone (Figure 4b ).
Murine retroviral insertional mutagenesis studies have identified wild-type MEF2D as a candidate oncogene involved in leukemogenesis. 14 The location of MEF2D at the breakpoint of a chromosome translocation in human acute lymphoblastic leukemia, 4, 5 and the current studies demonstrating potent transforming properties of both resultant MEF2D protein chimeras establish that MEF2D has latent oncogenic properties. Members of MEF2 protein family interact with a variety of other Cooperative transformation by MEF2D/DAZAP1 and DAZAP1/MEF2 V Prima and SP Hunger proteins involved in transcriptional regulation including histone deacetylases, p300 and Cabin1/Cain. [15] [16] [17] [18] MEF2 proteins are transcriptional effectors of mitogenic signaling pathways initiated by mitogen activated protein kinases including p38 and ERK5/Big mitogen activated protein kinase-1, and also play critical roles in calcium-regulated signaling pathways that control survival of neurons and T-cells. 6, 16, 19 MEF2 family proteins also play an important role in differentiation of hematopoietic cells. MEF2A and MEF2D levels increase markedly during differentiation of HL-60 cells into monocytes, and differentiation is suppressed by overexpression of dominantnegative form of MEF2D. 20 Since TS-2 expresses both MEF2D/DAZAP1 and DAZAP1/ MEF2D fusion transcripts, there are several potential mechanisms by which the chimeras might contribute to leukemogenesis. We demonstrated previously that MEF2D/DAZAP1 is a substantially more potent transcriptional activator than wild-type MEF2D, 5 and found in this study that MEF2D/ DAZAP1, but not wild-type MEF2D, transformed NIH 3T3 cells. These data suggest that MEF2D/DAZAP1 is a gain-of-function mutation that might directly activate transcription of genes critical for lymphocyte growth and/or survival such as c-jun 21 or interleukin-2, a known transcriptional target of MEF2D in T-cells; 22 as well as Ig J 23, 24 and Ig l 25 in B cells. Our data also establish that DAZAP1/MEF2D has oncogenic properties in vitro, suggesting that it also may be critical for leukemogenesis. DAZAP1/MEF2D proteins expressed in TS-2 retain sequence-specific RNA-binding properties related to DAZAP1 N-terminal domains. 5 Recently DAZAP1 was identified as a physiological substrate for extracellular signalregulated kinase-1/extracellular signal-regulated kinase-2 26 that interacts specifically with AU-rich elements found in mRNA of a number of pro-inflammatory cytokines (such as tumor necrosis factor a, interleukin-6 and interleukin-8) and immediate-early genes (such as c-fos) affecting their stability/translation. 27 Some reports discuss likely post-transcriptional mechanisms involving shuttling RNA-binding proteins in leukemogenesis. 28 A number of other genes that encode proteins with RNA-binding domains are rearranged in human cancer. 29 As is the case in TS-2, each of these RNA-binding proteins is fused to a transcription factor with DNA-binding properties, but there is no clear understanding whether, and if so how, their RNA-binding properties contribute to transformation.
Our studies establish that both MEF2D/DAZAP1 and DA-ZAP1/MEF2D have oncogenic properties and that co-expression of these proteins is synergistic. Mechanistically, both fusion proteins facilitate anchorage-independent growth in soft agar. MEF2D/DAZAP1 is associated with increased apoptosis and poor growth under low serum conditions, effects that may be complemented by DAZAP1/MEF2D, which facilitates growth and blunts apoptosis in low serum concentrations. Cooperative transformation by MEF2D/DAZAP1 and DAZAP1/MEF2 V Prima and SP Hunger
